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Abstract
 Background and Aims—Amoxicillin–clavulanate (AC) is the most frequent cause of 
idiosyncratic drug-induced injury (DILI) in the US DILI Network (DILIN) registry. Here, we 
examined a large cohort of AC-DILI cases and compared features of AC-DILI to those of other 
drugs.
 Methods—Subjects with suspected DILI were enrolled prospectively, and cases were 
adjudicated as previously described. Clinical variables and outcomes of patients with AC-DILI 
were compared to the overall DILIN cohort and to DILI caused by other antimicrobials.
 Results—One hundred and seventeen subjects with AC-DILI were identified from the cohort 
(n = 1038) representing 11 % of all cases and 24 % of those due to antimicrobial agents (n = 479). 
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Those with AC-DILI were older (60 vs. 48 years, P < 0.001). AC-DILI was more frequent in men 
than women (62 vs. 39 %) compared to the overall cohort (40 vs. 60 %, P < 0.001). The mean time 
to symptom onset was 31 days. The Tb, ALT, and ALP were 7 mg/dL, 478, and 325 U/L at onset. 
Nearly all liver biopsies showed prominent cholestatic features. Resolution of AC-DILI, defined 
by return of Tb to <2.5 mg/dL, occurred on average 55 days after the peak value. Three female 
subjects required liver transplantation, and none died due to DILI.
 Conclusion—AC-DILI causes a moderately severe, mixed hepatocellular–cholestatic injury, 
particularly in older men, unlike DILI in general, which predominates in women. Although often 
protracted, eventual apparent recovery is typical, particularly for men and usually in women, but 
three women required liver transplantation.
Keywords
Allergy; Amoxicillin; Augmentin; Clavulanic acid; Drug-induced liver injury; Liver toxicity
 Introduction
Idiosyncratic drug-induced liver injury (DILI) due to exposure to amoxicillin–clavulanate 
(AC) is observed relatively frequently. The US Drug Induced Liver Injury Network (DILIN) 
[1] and the Spanish DILI Registry [2] have identified AC as the most common cause of non-
acetaminophen DILI. The incidence of AC-DILI was recently determined in a 2-year 
prospective study in Iceland where medication prescriptions for the entire population 
(approximately 250,000) are tracked [3]. Of the 35,000 patients who were treated, 15 cases 
of AC-DILI were identified, corresponding to 1 in 2350 patients (43 cases per 100,000). If 
one assumes generalizability to the USA where more than 70 million Americans are treated 
each year with AC, this would suggest that there may be nearly 30,000 cases of DILI due to 
AC annually in the USA [4].
The clinicopathologic presentation and natural history of AC-DILI are variable, but, as with 
other penicillins, the illness is most often a cholestatic liver injury. Symptoms of cholestatic 
hepatitis (e.g., fatigue, loss of appetite, itching) predominate [2, 5, 6]. Histologically, a 
spectrum of cholestatic liver injury can occur that includes pure intrahepatic cholestasis, and 
mixed hepatitic/cholestatic injury, which, occasionally, may evolve into vanishing bile duct 
syndrome [7, 8]. Jaundice is typical of patients with AC-DILI reported in the literature; most 
recover fully, although death or need for liver transplant may occur [9, 10]. The US DILIN 
cohort, established in 2004, now consists of over 1450 cases of DILI, of which 11 % are due 
to AC. The chief aim of this work is to describe the clinical, laboratory, and 
histopathological features associated with AC-DILI in the USA. We have focused 
particularly on characterizing AC-DILI compared to DILI due to other antibiotics. 
Moreover, as the largest prospective series of AC-DILI to date, we also describe the three 
cases from our cohort that required liver transplantation and the twelve cases that evolved 
features of chronic DILI. We contrast features of AC-DILI between men and women, 
amoxicillin alone, and also discuss histopathological features of the 30 subjects who had 
liver biopsies. These data advance our current understanding of the clinical phenotype and 
further highlight unique features of AC-DILI.
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 Methods
 Study Design
The DILIN protocol has been previously described in detail [11]. Each participating center 
maintains active IRB approval, and all subjects enrolled provide written informed consent. 
Study subjects must have had exposure to a drug or herbal agent raising suspicion for DILI 
and must meet pre-specified criteria for severity of liver injury based upon biochemical 
testing. The onset of DILI is taken to be the date on which subjects had laboratory 
abnormalities that qualified them for enrollment, as previously described [11]. The pattern of 
liver injury is assessed by the ratio (R) of the serum ALT to alkaline phosphatase (both 
expressed as multiples of the ULN): By convention, an R < 2 indicates cholestatic-type 
injury, an R > 5 hepatocellular, and R = 2–5 as mixed cholestatic-hepatocellular injury. 
Chronic DILI is defined as laboratory, imaging, or physical examination evidence of 
continuing liver injury and disease ≥6 months after onset [12]. Liver biopsies, when 
performed, were initially reviewed in a blinded fashion by a single experienced 
hepatopathologist [DEK]. A second, unblinded review of biopsies was performed after cases 
were identified for this series.
 Causality
The cases described here were adjudicated between October 2004 and July 2014. The causal 
relationship between AC and the liver injury event was evaluated in a formal and 
standardized fashion by the DILIN Causality Committee as described [11, 13]. The 
likelihood of DILI in individual cases is assessed as definite (≥95 % likelihood), highly 
likely (75–94 % likelihood), probable (50–74 % likelihood), possible (25–49 % likelihood), 
or unlikely (<25 % likelihood). In this analysis, we included only the 117 cases adjudicated 
as being definitely, highly likely, or probably due to AC. The cases adjudicated as possibly 
(n = 5) and unlikely (n = 3) due to AC were excluded.
 Statistics
Descriptive statistics of demographic and clinical data of AC cases in comparison with other 
agents were generated and analyzed. The data are expressed as mean ± SD, range, 
frequencies, and percentages. Statistical significance among groups was determined by 
Wilcoxon rank-sum test for continuous variables, Fisher’s exact for binary variables, and 
Chi square for categorical variables. The LOESS regression model was used to fit smooth 
curves (and 95 % confidence intervals of the curves) of the R value at DILIN onset through 
275 days of follow-up for men and women ≥50 and <50 years. Differences with a P value 
<0.05 were considered statistically significantly different. SAS 9.4 [SAS Institute, Cary, NC] 
was used for all statistical analyses.
 Results
 Clinical Features of Amoxicillin–Clavulanate (AC) DILI (AC-DILI)
In the DILIN cohort, 117/1038 patients with DILI were determined to be definitely (n = 57), 
highly likely (n = 51), or probably (n = 9) due to AC (Table 1; Fig. 1). AC constituted the 
most common implicated medication in DILIN; the 117 patients with AC-DILI represented 
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24 % of all antimicrobial agents (n = 479) and 11 % of all drugs adjudicated within the 
entire registry (n = 1038).
In comparison with other antimicrobial causes of DILI, the mean age of subjects developing 
AC-DILI was significantly greater (60 vs. 48 years, P < 0.001) (Table 1). Men (72/117, 
62 %) more frequently developed AC-DILI than women (45/117, 39 % P < 0.001). This 
gender distribution was also significantly different than DILI ascribed to other 
antimicrobials (men = 36 %, P < 0.001). Among men and women, 82 % of cases occurred in 
persons aged 50 years of age or older (Supplemental Table 1). All other drugs in DILIN had 
an age and gender distribution similar to other antibiotics and significantly different than the 
AC-DILI cases (Table 1). Over 90 % of AC-DILI events occurred in study subjects who self-
reported their race as Caucasian, whereas the corresponding frequency for the overall study 
population was 78 % (P = 0.002).
The median number of days to symptom onset after drug initiation was 29, with all but two 
cases occurring within 12 weeks after initial drug exposure. For other antimicrobials, the 
corresponding latency was 29 days as well (P = 0.19). For the remaining agents in the 
DILIN cohort, the latency was 51 days (P < 0.001), (Table 1). Jaundice and pruritus were 
each reported in over 80 % of patients with AC-DILI. In fact, 23 % of subjects (27/117) 
underwent baseline evaluation for biliary obstruction with ERCP and/or MRCP. Cholestatic 
features were significantly less common in all other cases of DILI (jaundice—68 %, P < 
0.001; pruritus—50 %, P < 0.001).
 Pattern of Laboratory Testing and Evolution Over Time
The results of laboratory tests at the date of onset revealed a cholestatic or mixed cholestatic-
hepatocellular liver injury pattern in the majority of patients. The median R value at the time 
of DILIN onset was 2.7 (Table 2). Only 29/114 (25 %) AC cases had a hepatocellular injury 
pattern at onset (R value >5). The R value at symptom onset date corresponds to a median 
serum ALT of 362 U/L, AST of 171 U/L, ALP of 288 U/L, and TB of 6 mg/dL (Table 2). 
Eighteen percent of subjects with AC-DILI had a positive antinuclear antibody, and 15 % 
had a positive anti-smooth muscle antibody [ASMA]. More men (15/67, 22 %) than women 
(1/42, 2.4 %) among the AC-DILI cohort tested positive for ASMA (P < 0.001). Of a total of 
32 patients with either a positive ANA or ASMA, 7 subjects received corticosteroids. Of the 
remaining 85 subjects with AC-DILI, an additional 14 received treatment with 
corticosteroids in spite of negative serologies.
Serum ALT and AST levels peaked quickly after onset (4 and 5 days), while ALP and TB 
values peaked at 17 and 12 days, respectively (Fig. 2). Aminotransferase levels improved on 
average more quickly than ALP and TB, with a 50 % reduction from peak value occurring 
within 30 days for both ALT and AST and normalizing on average by day 90. The mean 
number of days until the total bilirubin improved by 50 % from its peak value was 18, with 
biochemical resolution, defined as TB <2.5 mg/dL, occurring on average at 55 days. ALP 
levels were the slowest to resolve with a 50 % improvement by 43 days and normalization 
on average not until 114 days after onset. LOESS curves of the R value from onset until day 
275 for men and women (<50 and ≥50 years) showed that women on average had a higher R 
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value at onset and that the R value decreased in all groups as disease evolved (Supplemental 
Figure 1).
 Severity and Outcome of Amoxicillin–Clavulanate (AC)-Induced DILI
The majority (88 %) of AC-DILI cases fell into the DILIN severity category of “moderate” 
liver injury, defined by enzyme elevations and jaundice with (46/117, 39 %) or without 
(57/117, 49 %) hospitalization (Table 1). Three men, all of whom were ≥50 years old, 
developed severe DILI, defined by evidence of coagulopathy or encephalopathy. Two fully 
recovered, while the other evolved features of chronic cholestasis. Three women (3/45, 
6.6 %), ranging in age from 49 to 67 years, required liver transplantation, which was nearly 
statistically different compared to men (0/72, 0 %, P < 0.0545). There were several features 
that appeared to differentiate these patients from the others in the cohort (Supplemental 
Table 2). The most important is that patients with severe AC-DILI had evidence of severe 
hepatocellular injury with markedly elevated aminotransferases and markedly elevated total 
bilirubin levels at presentation. One patient with AC-DILI died, but this was not ascribed to 
DILI and rather to metastatic lung cancer after resolution of liver injury. In contrast to all 
other drugs adjudicated in the DILIN cohort, severe and fatal cases of AC-DILI were less 
common 6 % (7/117) versus 28 % (262/921), P < 0.001).
Twelve subjects (11 %) developed chronic DILI, and their clinical characteristics are 
summarized in Table 3. All subjects presented with jaundice, 11 with itching, 5 with nausea, 
and 3 each with abdominal pain, fever and rash. Ten subjects (83 %) with chronic AC-DILI 
were male as compared with 62 (59 %) of 105 subjects without chronic DILI, P = 0.13. All 
other patient characteristics, such as age, race and weight, and liver injury characteristics, 
including latency, aminotransferases at onset and peak of injury, injury pattern and 
symptoms, were similar in subjects with and without chronic AC-DILI, with no evident 
predictors of chronic AC-DILI. Aminotransferases normalized within 2–3 years in 5 subjects 
with chronic DILI, and 4 subjects had asymptomatic but persistent mild abnormalities in 
aminotransferases (Table 3). Three subjects did not follow up after the initial study visit, 
including 2 subjects with asymptomatic mild elevations in aminotransferases 8 months post-
DILI onset, and 1 subject who was evaluated for liver transplantation due to DILI who was 
alive 2 years post-DILI onset with improved but persistently abnormal aminotransferases (no 
other clinical information was available).
 Concomitant Medications and AC-DILI Versus Amoxicillin-DILI
In the 2 months prior to AC-DILI onset, the percentage of subjects taking concomitant 
medications was 23 % (0–2 meds.), 35 % (3–5 meds.), and 42 % (>5 meds.). Of note, 42 % 
(49/117) of subjects reported a history of any prior drug allergy. Only one patient reported 
prior exposure to AC, 2 years prior to the implicated DILI event. An analysis of subjects 
with AC-DILI with prior AC, PCN, or cephalosporin exposure (n = 5) to cases without 
documented prior PCN/cephalosporin class exposure (n = 112) did not find any significant 
differences between the two groups (data not shown). In our DILIN registry, there were 8 
cases of DILI attributed to amoxicillin only (Supplemental Table 3). The 8 cases were 
younger than the corresponding AC-DILI cases (51 vs. 60 years, P = 0.03) and were more 
likely to present with a rash (63 vs. 22 %, P = 0.02). DILI onset with amoxicillin tended to 
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be abrupt compared to AC (median 17 vs. 29 days, P = 0.07) and resolution of DILI defined 
by improvement in TB from peak to 50 % reduction from peak was also more rapid (median 
5 vs. 8 days, P = 0.02). Three of the eight amoxicillin cases received a severe DILIN 
Severity score, but none were fatal or required liver transplantation.
 Histopathological Findings
Thirty liver biopsies and one explanted liver obtained during the period of acute injury were 
available for histological review. The biopsies were obtained a median 9 days after protocol-
defined onset (range −35 to 35) and a median 38 days after the first dose of AC (range 17–82 
days). The one explant was obtained 4 days after onset, but 132 days after the first dose of 
AC. Supplemental Table 4 shows the distribution of histopathological patterns of injury 
compared with the biochemical injury at onset. Most of the biopsies showed cholestatic 
patterns of injury, with 20 showing cholestatic hepatitis (Fig. 3), 3 showing acute cholestasis 
and 5 chronic cholestasis. Three patients had atypical histopathological patterns; 2 with 
acute hepatitis and the explant with fulminant hepatitis and extensive necrosis. Visible 
canalicular and hepatocellular bile accumulation in zone 3 was a common feature, present in 
28 cases (90 %) and was sufficiently severe that it was observed at low magnification in 13 
cases. Duct injury, often severe, was seen in 25 (83 %) cases. Three cases showed some 
evidence of duct paucity during this acute injury period, but they did not develop chronic 
DILI. The inflammation (portal and lobular) was generally mild except in the cases of acute 
and fulminant hepatitis. Immuno-allergic features (eosinophils and granulomas) were noted 
in 21 and 28 cases, respectively, and although no cases were classified as granulomatous 
hepatitis, 4 cases did show large epithelioid granulomas. Although 12 cases showed some 
degree of periportal fibrosis, none had bridging fibrosis or cirrhosis. Three patients had one 
or two follow-up biopsies after the acute injury period. Two were taken at 2 months after the 
first dose of AC revealed cholestatic hepatitis with findings similar to those described above. 
The remaining two follow-up specimens were from the same patient, taken 108 and 289 
days after the first dose of AC. Both revealed chronic cholestasis, with strong staining for 
copper and pseudoxanthomatous changes in hepatocytes, but normal numbers of bile ducts.
 Discussion
Here, we have demonstrated that AC is the most common cause of idiosyncratic liver injury 
in the DILIN data set and that, like other penicillins and cephalosporins, it causes 
predominantly a cholestatic-type liver injury [5, 14]. In addition, DILI due to AC, unlike 
DILI due to other drugs, appears to preferentially afflict older men. In the Spanish DILI 
Registry [15], the gender distribution was found to be nearly equal (52 % men and 48 % 
women). In contrast, earlier published case series from the USA [16], Belgium [17], and 
France [18] reported men to have predominated (Table 4). In the Spanish cohort, patients 
≥55 years old were significantly more likely to develop a cholestatic (R value <2) or mixed 
(R value >2 but <5) liver injury. Our findings corroborate the Spanish experience since the R 
value at onset among those 50 years of age or older was 3.3 for men and 4.9 for women in 
contrast to 7.6 and 6.3, among men and women less than 50 years of age (Supplemental 
Table 1). We found similar results if we used the age cutoff of 55 years, but chose 50 
because this is the average age of menopause for women in the USA. Interestingly, among 
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the 6 severe cases, all three who required liver transplantation were women. On the other 
hand, 83 % (10/12) of all chronic DILI cases were in men. These differences highlight the 
possibility that epigenetic changes due to age and gender could play a role in the outcome 
from AC-DILI. Importantly though, we found that the majority of patients eventually 
recover fully.
The vast majority of our cases showed prominent zone 3 cholestasis and bile duct injury 
with mild inflammation, as described by others [18]. Granulomas and/or eosinophils, which 
are often associated with and thought to be consistent with immuno-allergic injury, were 
relatively common. Three cases, all women, had atypical histological findings, with two 
cases showing acute hepatitis (without cholestasis) and one explanted liver showing 
fulminant hepatitis with extensive necrosis.
In assessing the cause of acute liver injury, it is important to consider drugs and chemicals as 
potential causative agents, but also to exclude other more common causes, such as viral 
hepatitis, alcohol, hypoxemia/ischemia, or gallstones or other biliary tract disorders. Another 
confounding factor in causality assessment is the high frequency of polypharmacy, with 
many subjects receiving multiple drugs and botanical, herbal, and dietary supplements. In 
the US DILIN, we have developed and refined an approach to causality assessment over 
several years that takes advantage of expert opinion and of the collective wisdom and 
accumulated data of the Network. Because of the typical “signature” and high frequency of 
liver injury due to AC, we likely ascribe relatively high likelihood scores to such cases.
In recent work from DILIN, we have shown that AC and other agents associated with 
immuno-allergic injury cause hepatitis with infiltration of portal triads by many T cells, most 
of which are CD8+ cytotoxic T cells [19]. These and other findings suggest that the 
pathogenesis of the liver injury is primarily an immune-mediated attack on cholangiocytes 
or perhaps on the apical pole of hepatocytes. The specific antigens against which a cellular 
immune response is mounted currently remain unknown, but it seems likely that they 
represent neo-antigens produced by the beta-lactam structures of amoxicillin or clavulanic 
acid, perhaps, reacting with proteins of the susceptible hosts. While neo-antigens may form 
in many people who take AC, DILI may occur in only a small subset with specific genetic 
susceptibilities. Genetic variation at human leukocyte antigen (HLA) class I & II loci has 
been shown to be associated with AC-DILI [17, 20]. The strongest association thus far 
identified is at a single nucleotide polymorphism in the gene encoding the class II HLA-
DRB1* 1501-DQB1* 0602 allele. A more recent analysis of genotype–phenotype 
interaction in AC-DILI cases found that the class I alleles A*3002 and B*1801 were more 
frequently associated with hepatocellular injury compared to controls, while the presence of 
the DRB1*1501-DQB1*0602 allele was significantly increased in cholestatic/mixed cases 
[21]. Thus, clinical, histopathological, and genetic data point to the importance of the 
adaptive immune response in the pathogenesis and course of DILI due to AC. The genetic 
associations, although striking, are not of sufficient power to provide a priori prediction of 
who is at high risk to develop DILI due to AC, based solely upon HLA typing. Even in the 
case of DILI due to another penicillin, flucloxacillin, in which an 80-fold risk has been 
established for persons with HLA-B*5701, prior screening before administration of the drug 
is not considered clinically warranted [22]. While the association between genetic variation 
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at HLA loci in AC-DILI has been reproduced, other investigations into the contribution of 
genetic variation and the risk of DILI have been negative [23].
An uncertainty is whether the DILI due to AC is actually due to amoxicillin or to clavulanate 
or to both together. The eight cases of DILI due only to amoxicillin showed similar clinical, 
biochemical, and other features as those of the AC cohort, suggesting that amoxicillin alone, 
like virtually all penicillins or cephalosporins, is capable of causing cholestatic or mixed-
type DILI (Supplemental Table 3). Then, too, clavulanic acid itself also has a beta-lactam 
ring, and it may give rise to neo-antigen[s] that can call forth a pathological adaptive 
immune response in susceptible hosts. In others it may act chiefly to slow the clearance and 
to increase the levels of amoxicillin, thus helping to give rise to a neo-antigen derived from 
amoxicillin.
Strengths of our study include its prospective nature with good follow-up; most surviving 
subjects agreed to return at 6 months and beyond if there was evidence of chronic DILI. The 
assessment of both severity and causality were done systematically using a Delphic process. 
In addition, all liver biopsies were reviewed by a single expert hepatopathologist [DEK] 
without prior reference to the clinical or laboratory features. We also recognize some 
limitations. One was that as per the DILIN protocol, liver biopsies are not required (but are 
performed as part of routine clinical care), and thus we do not have liver histology on all 
subjects. Despite this potential limitation, we doubt that the absence of histology on all 
subjects would change our conclusions. While not a limitation, a potential criticism is that 
our study was not a population-based study. Thus, subjects were identified at or referred to 
only a limited number of clinical sites (variably 5–8 in number over the years of the study). 
This may have led to recall or reporting bias since it is likely that not all patients with AC-
DILI were referred to a DILIN site. Notwithstanding, given the large sample size, again it is 
unlikely that such a bias would change our conclusions.
In summary, AC is the most frequent cause of idiosyncratic DILI in the USA, and, indeed, 
probably throughout the world. Unlike most DILI, AC causes DILI more often in older men, 
with Caucasian men seeming to be at greatest risk. The clinical presentation is that of 
immuno-allergic type injury with prominent cholestatic features and chemistries. The initial 
levels of serum ALT and the R values tend to be higher both in women and men <50 years 
old versus those ≥50 years old, although these differences are not statistically significant. 
The prognosis is generally good. Nevertheless, a small proportion of patients develop acute 
liver failure and die or require liver transplantation. Ten percent of subjects continue to have 
ongoing evidence of liver injury 6 months after onset. The higher risk especially in older 
Caucasian men is worthwhile noting as is the finding that only three subjects, all of whom 
were women, required liver transplantation.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Flow diagram of amoxicillin–clavulanate DILI patients. Patients with DILI from the US 
DILIN, October 2004–July 2014, with complete adjudication (n = 1038) are shown. The 
number of patients with DILI due to amoxicillin–clavulanate and the severity of injury with 
ultimate outcomes are shown
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Fig. 2. 
Time course of AC-DILI presented as box and whisker plot: ALT peak must be ≥×5 ULN or 
×5 baseline, AST peak must be ≥×5 ULN or ×5 baseline, ALP must be ≥×2 ULN or ×2 
baseline, TB peak must be ≥2.5 mg/dL. Biochemical resolution defined as ALT, AST, or 
ALP below ULN; TB <1.2 mg/dL
deLemos et al. Page 12
Dig Dis Sci. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
Representative histopathologic findings of cholestatic hepatitis due to amoxicillin–
clavulanate. a Portal inflammation with cholestasis (arrowhead). b Portal inflammation with 
injured duct. c Lobular inflammation and apoptotic hepatocyte (arrow). d Canalicular 
cholestasis (arrowheads). ALP serum alkaline phosphatase, ALT serum alanine 
aminotransferase, AST serum aspartate aminotransferase, SD standard deviation, TB serum 
total bilirubin, ULN upper limit of normal
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Table 2
Selected laboratory features of AC-DILI
Laboratory feature At onset date Range Peak value from onset to 6 month visit Range
ALT (U/L), [median (IQR)] 362 (201–528)   52–3890 405 (211–648)   52–3890
AST (U/L), [median (IQR)] 171 (102–308)   33–5990 201 (125–371)   47–7525
Alkaline phosphatase (U/L), [median IQR (SD)] 288 (210–380) 123–1005 361 (252–551) 144–1472
Total bilirubin (mg/dL), [median (IQR)]     6 (4–9)  0.5–26   13 (7–23)  0.5–45
INR [median (IQR)]  0.9 (0.9–1.1)  0.8–4  1.1 (1.1–1.2)  0.8–9
R value at onset [median (IQR)]  2.7 (1.7–5)  0.5–44
R value <2 n (%)   37 (33)
R value >2 and <5 n (%)   48 (42)
R value >5 n (%)   29 (25)
Positive HCV RNA n (%)     2 (3 %)
Positive ANA n (%)   20 (18 %)
Positive ASMA n (%)   16 (15 %)
Serum IgG (mg/dL) [median (IQR)] 995 (793–1166) 478–2840
Absolute eosinophil count (/uL) [median (IQR)] 228 (99–357)     0–1253
Dig Dis Sci. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
deLemos et al. Page 17
Ta
bl
e 
3
Se
le
ct
ed
 fe
at
ur
es
 o
f c
hr
on
ic
 A
C-
D
IL
I
A
ge
 a
nd
 g
en
de
r
La
te
nc
y 
(d
ay
s)
A
LT
 a
t 
D
IL
I 
o
n
se
ta
A
ST
 a
t 
D
IL
I 
o
n
se
ta
A
LP
 a
t 
D
IL
I 
o
n
se
ta
T.
Bi
li 
at
 
D
IL
I 
o
n
se
ta
Li
v
er
 in
jur
y 
pa
tte
rn
 a
t 
D
IL
I o
ns
et
In
te
rv
a
l f
ro
m
 D
IL
I 
o
n
se
t t
o 
ab
no
rm
al
 
a
m
in
ot
ra
ns
fe
ra
se
s 
de
fin
in
g 
ch
ro
n
ic
 
D
IL
I (
mo
nt
hs
)
A
bn
or
m
al
 
a
m
in
ot
ra
sn
fe
ra
se
s 
de
fin
in
g 
ch
ro
n
ic
 D
IL
Ia
D
IL
I o
ut
co
m
es
a
54
 M
 
 
29
61
0 
(12
.2)
22
4 
(5)
23
9
 
 
4.
4 
(4.
4)
H
ep
at
oc
el
lu
la
r
 
 
6
A
LT
 8
6 
(1.
9),
 A
ST
 67
 
(1.
5)
N
or
m
al
 li
v
er
 b
io
ch
em
ist
rie
s 
3 
ye
ar
s p
os
t-D
IL
I
71
 M
 
 
34
75
5 
(11
.4)
30
8 
(8.
3)
33
7 
(3.
7)
 
 
8.
8 
(8.
8)
M
ix
ed
 
 
7
A
LT
 6
3 
(1.
4),
 A
ST
 45
 
(1.
1),
 T.
B
ili
 2
.1
 (2
.1)
N
or
m
al
 li
v
er
 b
io
ch
em
ist
rie
s 
2 
ye
ar
s p
os
t-D
IL
I
71
 M
 
 
27
20
2 
(3.
2)
14
3 
(3.
5)
17
8 
(2)
 
 
4.
6 
(3.
8)
Ch
ol
es
ta
tic
 
 
6
A
ST
 4
5 
(1.
1 U
LN
), T
.
B
ili
 
1.
3 
(1.
1 U
LN
)
N
or
m
al
 li
v
er
 b
io
ch
em
ist
rie
s 
2 
ye
ar
s p
os
t-D
IL
I, 
fib
ro
sc
an
 
su
gg
es
te
d 
fa
tty
 li
v
er
 b
u
t n
o 
sig
ni
fic
an
t f
ib
ro
sis
60
 M
 
 
23
38
7 
(8.
6)
13
4 
(3.
8)
28
6
 
 
7.
7 
(7)
M
ix
ed
 
 
8
A
LT
 5
5,
 A
ST
 4
1
N
or
m
al
 li
v
er
 b
io
ch
em
ist
rie
s 
2 
ye
ar
s p
os
t-D
IL
I, 
w
ith
 fa
tty
 
ap
pe
ar
in
g 
liv
er
 b
y 
u
ltr
as
ou
nd
 1
 y
ea
r p
os
t-D
IL
I
32
 M
 
 
12
37
5 
(5.
6)
 
 
11
 (1
.7)
19
8 
(1.
7)
 
 
4.
7 
(4.
7)
M
ix
ed
 
 
6
A
LT
 8
7 
(2.
5),
 A
ST
 49
 
(1.
6),
AL
P 1
65
 (1
.3)
A
sy
m
pt
om
at
ic
 a
bn
or
m
al
 
A
LT
 6
4,
 w
ith
 n
or
m
al
 li
v
er
 
u
ltr
as
ou
nd
 2
 y
ea
rs
 p
os
t-
D
IL
I
39
 F
 
 
 
 
3
27
1 
(6.
8)
 
 
88
 (2
.4)
30
2 
(2.
6)
 
 
5.
3 
(4.
4)
M
ix
ed
 
 
7
A
LT
 7
1 
(2)
, A
ST
 92
 (2
.5)
, 
A
LP
 6
44
 (5
.5)
, T
.
B
ili
 1
.8
 
(1.
5)
A
sy
m
pt
om
at
ic
 a
bn
or
m
al
 
A
LT
 6
5 
(1.
4) 
an
d T
.
B
ili
 1
.3
 
(1.
1) 
2 y
ea
rs 
po
st-
DI
LI
72
 F
 
 
33
12
6 
(3.
6)
 
 
70
 (1
.9)
29
9 
(2.
6)
 
 
3.
8 
(3.
2)
Ch
ol
es
ta
tic
 
 
8
A
ST
 4
1 
(1.
2)
Su
bje
ct 
did
 no
t fo
llo
w
 u
p 
af
te
r f
irs
t s
tu
dy
 v
isi
t b
u
t w
as
 
as
ym
pt
om
at
ic
 a
t l
as
t v
isi
t
40
 M
 
 
47
20
4 
(3.
9)
88
 (2
.4)
18
2 
(1.
6)
 
 
5.
8 
(4.
8)
M
ix
ed
 
 
8
A
LT
 8
4 
(1.
6),
 A
LP
 13
9 
(1.
2)
Su
bje
ct 
did
 no
t fo
llo
w
 u
p 
af
te
r f
irs
t s
tu
dy
 v
isi
t
63
 M
<
14
20
8 
(3.
2)
 
 
95
 (2
.3)
49
0 
(3.
6)
10
.2
 (1
0.2
)
Ch
ol
es
ta
tic
 
 
6
A
LT
 7
8 
(1.
4),
 A
ST
 10
0 
(2.
4),
 A
LP
 92
8 (
5.8
), 
T.
B
ili
 1
7.
6 
(12
.6)
In
iti
al
 in
te
nt
 to
 li
st 
fo
r l
iv
er
 
tr
an
sp
la
nt
 w
as
 li
m
ite
d 
by
 
ca
rd
ia
c 
co
m
or
bi
di
tie
s. 
Th
e 
su
bje
ct 
wa
s 
al
iv
e 
w
ith
 
ab
no
rm
al
 A
LT
 7
1,
 A
ST
 4
8,
 
A
LP
 2
63
, T
.
B
ili
 1
.5
 2
 y
ea
rs
 
af
te
r D
IL
I o
ns
et
36
 M
 
 
29
35
2 
(6.
3)
20
1 
(5.
7)
20
4 
(1.
6)
 
 
8.
2 
(6.
3)
M
ix
ed
10
A
LT
 1
02
 (1
.8)
, A
ST
 80
 
(2.
3),
 A
LP
 14
2 (
1.1
)
A
sy
m
pt
om
at
ic
 a
bn
or
m
al
 
A
LT
 7
1 
an
d 
A
LP
 1
89
 2
 
ye
ar
s p
os
t-D
IL
I
66
 M
 
 
22
23
5 
(5.
9)
23
7 
(6.
4)
47
3 
(4.
04
)
13
.1
 (1
3.1
)
Ch
ol
es
ta
tic
 
 
8
A
LT
 5
1 
(1.
1),
 A
LP
 15
0 
(1.
25
)
N
or
m
al
 li
v
er
 b
io
ch
em
ist
rie
s 
2 
ye
ar
s p
os
t-D
IL
I
Dig Dis Sci. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
deLemos et al. Page 18
A
ge
 a
nd
 g
en
de
r
La
te
nc
y 
(d
ay
s)
A
LT
 a
t 
D
IL
I 
o
n
se
ta
A
ST
 a
t 
D
IL
I 
o
n
se
ta
A
LP
 a
t 
D
IL
I 
o
n
se
ta
T.
Bi
li 
at
 
D
IL
I 
o
n
se
ta
Li
v
er
 in
jur
y 
pa
tte
rn
 a
t 
D
IL
I o
ns
et
In
te
rv
a
l f
ro
m
 D
IL
I 
o
n
se
t t
o 
ab
no
rm
al
 
a
m
in
ot
ra
ns
fe
ra
se
s 
de
fin
in
g 
ch
ro
n
ic
 
D
IL
I (
mo
nt
hs
)
A
bn
or
m
al
 
a
m
in
ot
ra
sn
fe
ra
se
s 
de
fin
in
g 
ch
ro
n
ic
 D
IL
Ia
D
IL
I o
ut
co
m
es
a
63
 M
 
 
39
97
7 
(18
)
36
3 
(10
.7)
39
3 
(2.
6)
 
 
3.
5 
(2.
9)
H
ep
at
oc
el
lu
la
r
 
 
6
A
LT
 5
4 
(1.
2),
 A
ST
 44
 
(1.
05
), A
LP
 27
4 (
2.3
)
A
sy
m
pt
om
at
ic
 a
bn
or
m
al
 
A
LT
 5
5 
2 
ye
ar
s p
os
t-D
IL
I
A
LP
 a
lk
al
in
e 
ph
os
ph
at
as
e,
 D
IL
I d
ru
g-
in
du
ce
d 
liv
er
 in
jur
y, 
T.
Bi
li 
to
ta
l b
ili
ru
bi
n,
 M
 
m
al
e,
 F
 
fe
m
al
e
a V
al
ue
s o
f A
LT
,
 
A
ST
,
 
an
d 
A
LP
 re
po
rte
d 
in
 U
/L
 w
ith
 (m
ult
ipl
es 
of 
up
pe
r l
im
it o
f n
orm
al 
wh
en
 av
ai
la
bl
e),
 T.
B
ili
 re
po
rte
d 
in
 m
g/
dL
 w
ith
 (m
ult
ipl
es 
of 
up
pe
r l
im
it o
f n
orm
al 
wh
en
 av
ai
la
bl
e)
Dig Dis Sci. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
deLemos et al. Page 19
Ta
bl
e 
4
Su
m
m
ar
y 
of
 fe
at
ur
es
 o
f D
IL
I d
ue
 to
 A
C 
fro
m
 o
ur
 a
nd
 p
re
v
io
us
 p
ub
lis
he
d 
se
rie
s w
ith
 a
t l
ea
st 
10
 su
bje
cts
Au
th
or
Ty
pe
 o
f s
tu
dy
a
n
d 
lo
ca
tio
n
Ye
a
rs
 o
f
st
ud
y
N
um
be
r o
f
AC
-D
IL
I
ca
se
s
A
ge (ye
a
rs
,
m
ea
n
,
ra
n
ge
)
M
al
e
ge
nd
er
(%
)
La
te
nc
y
(d
ay
s)
(m
ea
n
(ra
ng
e))
Pr
es
en
ta
tio
n
w
ith jau
nd
ice
 (%
)
In
jur
y p
att
ern
ch
ol
es
ta
tic
/m
ix
ed
/
he
pa
to
ce
llu
la
r
D
ur
at
io
n 
of
 in
jur
y (
da
ys)
[m
ea
n (
ra
ng
e) 
un
les
s
o
th
er
w
ise
 sp
ec
ifi
ed
]
D
ea
th
 o
r
liv
er
tr
an
sp
la
nt
C
hr
o
n
ic
in
jur
y
(%
)
de
Le
m
os
 e
t a
l.
Pr
os
pe
ct
iv
e,
 U
SA
20
04
–2
01
4
11
7
59
 (1
3–
87
)
62
30
 (3
–1
29
)
87
32
/4
2/
25
 %
52
 (2
–5
34
) f
or 
hy
pe
rb
ili
ru
bi
ne
m
ia
*
3.
4 
%
 (1
 di
ed
, 3
 tr
an
sp
lan
t)
11
Lu
ce
na
 e
t a
l. 
[1
5]
Pr
os
pe
ct
iv
e,
 S
pa
in
19
95
–2
00
5
69
56
52
16
 (1
3–
20
)
81
31
/3
3/
36
 %
77
 (1
0–
30
0)
2.
9 
%
 (1
 di
ed
, 1
 tr
an
sp
lan
t)
8
D
e 
H
aa
n 
et
 a
l. 
[2
4]
R
et
ro
sp
ec
tiv
e,
19
82
–1
99
6
40
61
70
22
 (m
ax
 55
)
90
46
 (1
0–
16
8)
N
on
e
Th
om
so
n 
et
 a
l. 
[2
5]
R
et
ro
sp
ec
tiv
e,
 A
us
tra
lia
19
86
–1
99
3
34
60
58
B
jor
nss
en
 et
 al
. [3
]
Pr
os
pe
ct
iv
e,
 Ic
el
an
d
20
10
–2
01
1
22
 o
f 9
6 
ca
se
s o
f D
IL
I
40
N
on
e
O
’D
on
oh
ue
 e
t a
l. 
[2
6]
R
et
ro
sp
ec
tiv
e,
 S
co
tla
nd
19
91
–1
99
7
22
59
 (4
3–
91
)
45
17
 to
 ja
un
dic
e (
3–
48
)
m
ed
ia
n 
69
 fo
r J
au
nd
ic
e t
o 
re
so
lv
e 
(29
–
15
0)
5.
6 
%
 (1
 di
ed
)
G
ar
ci
a-
Ro
dr
ig
ue
z 
et
 a
l. 
[2
7]
R
et
ro
sp
ec
tiv
e,
 S
pa
in
19
91
–1
99
2
21
43
76
75
 %
/N
A
/N
A
N
on
e
R
ed
dy
 e
t a
l. 
[1
6]
R
et
ro
sp
ec
tiv
e,
 U
SA
19
84
–1
98
7
18
59
 (3
3–
80
)
67
27
 (2
–4
5)
89
39
/3
3/
22
 %
N
on
e
La
rr
ey
 e
t a
l. 
[1
8]
R
et
ro
sp
ec
tiv
e,
 F
ra
nc
e
19
87
–1
99
0
15
64
 (3
9–
82
)
74
34
 (7
–8
9)
10
0
74
/1
3/
13
 %
7 
(4–
16
) w
ee
ks
N
on
e
Dig Dis Sci. Author manuscript; available in PMC 2016 August 01.
